Press Releases
Access strategic insights, industry indicators, and expert macro reports curated under Press Releases.
TROP-2 Targeted Therapy Market is anticipated to surpass USD 3.29 billion in 2031 at a CAGR of 8.6 %
The TROP-2 Targeted Therapy market is expanding rapidly due to increasing precision oncology adoption, rising cancer prevalence, and growing use of antibody-drug conjugates. North America leads the market, while Asia Pacific shows the fastest growth. Continuous clinical trials, regulatory approvals, and strategic collaborations are accelerating innovation and commercial adoption worldwide.
Second Primary Cancer Prevention Market is expected to reach USD 24.7 billion by 2031
The Second primary cancer prevention refers to strategies aimed at reducing the risk of developing a new, unrelated cancer in individuals with a prior cancer diagnosis. Growing cancer survivorship, advances in treatment, and increasing awareness of long-term health outcomes have heightened the importance of prevention and surveillance programs. Key approaches include routine screening, genetic risk assessment, lifestyle modification, and long-term follow-up care. Government agencies and healthcare organisations increasingly emphasise survivorship care plans and evidence-based screening protocols to detect new malignancies at earlier stages. Continued investments in early detection technologies and personalised risk assessment are expected to support advancements in second primary cancer prevention.
Synthetic Lethality Drug Market is expected to reach USD 4.31 billion by 2031
The worldwide market for Synthetic Lethality Drug Market is expected to witness significant growth due to an increasing adoption of precision oncology approaches as well as the rising prevalence of genetically driven cancers. Synthetic lethality-based therapies are considered efficient as they are transforming cancer treatment by targeting tumor-specific genetic vulnerabilities, which minimizes damage to healthy cells. Multiple growing investments in genomic research, next-generation sequencing technologies, and biomarker discovery are also accelerating their identification of novel synthetic legal targets. Additionally, increasing regulatory support for targeted therapies, advancements in companion diagnostics, as well as expansion of clinical trial activity are factors that are contributing to market expansion.
Cardio-Oncology Market is projected to surpass USD 5.92 billion in 2031 at a CAGR of 6.8%
The cardio-oncology market is expanding due to rising cancer prevalence and the growing need to manage cardiovascular complications caused by cancer therapies. Advances in cardioprotective drugs, supportive regulatory guidelines, increasing awareness, and ongoing research are driving market growth, with North America leading while the Asia Pacific emerges as a rapidly growing regional market.
Syndromic Infectious Disease Diagnostics Market is expected to reach USD 3.9 billion by 2031
The market for diagnosing syndromic infectious diseases is growing rapidly, as there are more multiplex molecular assays available that can simultaneously identify many pathogens from a single sample.
Antimicrobial Resistance Diagnostics Market is expected to reach USD 6.7 billion by 2031
The Antimicrobial Resistance (AMR) Diagnostics Market is expanding quickly because of the growing number of cases of drug-resistant infections and the increasing need for fast and precise diagnostic solutions. Advances in molecular diagnostics, PCR, next-generation sequencing, and point-of-care testing enable healthcare providers to identify resistant pathogens earlier and strengthen antimicrobial stewardship. Governments and healthcare organizations are increasing investments in healthcare infrastructure and AMR control initiatives, while rising hospital-acquired infections continue to accelerate market growth. On the other hand, expensive diagnostics, complicated regulations, and inadequate accessibility in low-resource areas may discourage adoption.
Pathogen Genomics Diagnostics Market is expected to reach USD 11.2 billion by 2031
The pathogen genomics diagnostics market is growing rapidly, as infectious diseases are becoming more prevalent, there is a growing need for fast and precise pathogen identification, and the use of genomic technologies in clinical diagnostics and public health surveillance is increasing. The development of next generation sequencing (NGS), polymerase chain reaction (PCR), whole genome sequencing (NGS) and metagenomic sequencing is allowing for more rapid and precise identification, characterization and monitoring of pathogens. Furthermore, rising attention to investigating outbreaks, screening for antimicrobial resistance, and surveillance for epidemics, sas well as growing investments in precision medicine research and public health infrastructure are driving market growth.
Pandemic Preparedness Diagnostics Market is expected to reach USD 5.5 billion by 2031
The worldwide market for pandemic preparedness diagnostic tools is booming, as national governments across the globe are making the effort to enhance their early detection of worldwide pandemics and to improve upon the lessons of COVID-19 around testing using multiplex and decentralised molecular diagnostic systems to support pandemic preparedness diagnostics. In January 2025, the World Health Organisation (WHO), Food and Agriculture Organisation (FAO), United Nations International Children's Fund (UNICEF) and the World Bank collectively launched an unprecedented multi-country initiative that will invest over 15 million USD for several areas (diagnostic readiness, multisectoral surveillance, and environmental monitoring) in the area of Southeast Asia. The extensive framework created by WHO for pandemic preparedness identifies diagnostics as a centrepiece of the emergency coordination, surveillance, and rapid response capabilities to global emergencies. Currently, due to the increasing investment in molecular testing, surveillance systems that utilize Artificial Intelligence, and multiplex PCR technology, there is a growing demand for scalable pandemic preparedness diagnostics worldwide.
Rapid Infectious Disease Testing Market is anticipated to surpass USD 60.8 billion in 2031 at a CAGR of 6.9%
The rapid infectious disease testing market is growing due to increasing demand for early diagnosis, outbreak control, and point-of-care testing. Rapid test kits and lateral flow assays dominate the market, while respiratory infections remain the leading application. North America leads globally, with Asia Pacific showing strong growth potential driven by healthcare investments.
Living Medicines and Microbial Therapeutics Market is expected to reach USD 2.5 billion by 2031
The market for living medicines and microbial therapeutics is rapidly growing, primarily because healthcare companies are continuously finding more applications of microbiome-based therapies to cure gastrointestinal, metabolic, immune, and infectious diseases. These treatments rely on the use of live microorganisms or genetically modified bacteria to exert a therapeutic effect directly in the human body, thereby providing an innovative alternative to the use of conventional pharmaceuticals. Increased funding for microbiome science, increase in investments in synthetic biology, and a wider range of products in clinical trials contribute to the increase of market size.
Lab-on-a-chip Diagnostic Systems Market is expected to reach USD 15.1 billion by 2031
The Lab-on-a-Chip Diagnostic Systems Market is growing rapidly as more people want quick, portable, and inexpensive diagnostic solutions in all healthcare environments. By combining various laboratory functions on a single microchip, these systems can deliver quicker results while using fewer samples and maintaining better accuracy. Besides that, ramping up the occurrence of infectious and lifestyle diseases, greater reliance on point-of-care testing, and progress in microfluidics and biosensor technologies are the main reasons for the market growth.
Bioengineered Proteins and Enzymes Market is expected to reach USD 11.5 billion by 2031
The rise in the demand for biological products like biologics, industrial enzymes, and sustainable bioprocessing solutions from the pharmaceutical, food & beverage, agriculture, and biotechnology industries are fueling the growth of these enzymes and proteins as bioengineered products. Proteins and enzymes with high efficiency and specific applications are being developed with ever increasing efficiency, thanks to the recombinant DNA technology, synthetic biology and protein engineering. Moreover, the growing investments for biopharmaceutical production, diversified application area in diagnostics and therapeutics, and the growing use of enzyme-based processes in the industrial sector are further pushing the market forward.